Agenus (NASDAQ:AGEN) Earns “Neutral” Rating from HC Wainwright

Agenus (NASDAQ:AGEN)‘s stock had its “neutral” rating reaffirmed by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports.

Separately, Robert W. Baird dropped their price target on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.75.

Agenus Stock Performance

Agenus stock opened at $1.73 on Tuesday. Agenus has a fifty-two week low of $1.64 and a fifty-two week high of $19.69. The firm has a 50 day moving average price of $3.07 and a 200 day moving average price of $3.71. The company has a market capitalization of $40.58 million, a PE ratio of -0.15 and a beta of 1.23.

Agenus (NASDAQ:AGEN) last posted its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, beating the consensus estimate of ($2.36) by $0.32. The company had revenue of $26.84 million during the quarter, compared to analyst estimates of $30.09 million. As a group, equities research analysts forecast that Agenus will post -12.55 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

Institutional investors have recently modified their holdings of the company. EP Wealth Advisors LLC purchased a new stake in shares of Agenus during the 3rd quarter worth $55,000. Corton Capital Inc. purchased a new stake in shares of Agenus during the 4th quarter worth $36,000. Point72 DIFC Ltd lifted its position in shares of Agenus by 380.0% during the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 11,542 shares during the last quarter. Virtu Financial LLC purchased a new stake in Agenus in the fourth quarter valued at $51,000. Finally, Apollon Wealth Management LLC purchased a new stake in Agenus in the fourth quarter valued at $55,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.